Cancer Letters
Volume 229, Issue 1 , Pages 25-31 , 8 November 2005

The CYP1A2-164A→C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans

  • Harald Moonen

      Affiliations

    • Department of Health Risk Analysis and Toxicology, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 43 388 1218; fax: +31 43 388 4146.
    • ,
  • Leopold Engels

      Affiliations

    • Department of Gastroenterology, Maasland Hospital, PO Box 5500, 6130 MB Sittard, The Netherlands
    • ,
  • Jos Kleinjans

      Affiliations

    • Department of Health Risk Analysis and Toxicology, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands
    • ,
  • Theo de Kok

      Affiliations

    • Department of Health Risk Analysis and Toxicology, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands

Received 25 October 2004 ,Revised 5 December 2004 ,Accepted 8 December 2004.

References 

  1. Cannon-Albright LA, Skolnick MH, Bishop DT, Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N. Engl. J. Med. 1988;319:533–537
  2. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer Incidence in Five Continents. vol. VII. Lyon: IARC Scientific Publications 143; 1997;
  3. McMichael AJ, Giles GG. Cancer in migrants to Australia: extending the descriptive epidemiological data. Cancer Res. 1988;48:751–756
  4. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 1981;66:1191–1308
  5. Giovannucci E, Stampfer EJ, Colditz G, Rimm EB, Willett WC. Relationship of diet to risk of colorectal adenoma in men. J. Natl Cancer Inst. 1992;84:91–98
  6. Kono S, Imanishi K, Shinchi K, Yanai F. Relationship of diet to small and large adenomas of the sigmoid colon. Jpn. J. Cancer. Res. 1993;84:13–19
  7. Goldbohm RA, van den Brandt PA, van't Veer P, Brants HA, Dorant E, Sturmans F, et al. A prospective cohort study on the relation between meat consumption and the risk of colon cancer. Cancer Res. 1994;54:718–723
  8. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat and fiber in relation to risk of colon cancer in men. Cancer Res. 1994;54:2390–2397
  9. Nagao M, Ushijima T, Watanabe N, Okochi E, Ochiai M, Nakagama H, et al. Studies on mammary carcinogenesis induced by a heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, in mice and rats. Environ. Mol. Mutagen. 2002;39:158–164
  10. Adamson RH, Thorgeirsson UP, Snyderwine EG, Thorgeirsson SS, Reeves J, Dalgard DW, et al. Carcinogenicity of 2-amino-3-methylimidazo[4,5-f]quinoline in nonhuman primates: induction of tumors in three macaques. Jpn. J. Cancer Res. 1990;81:10–14
  11. Ochiai M, Ogawa K, Wakabayashi K, Sugimura T, Nagase S, Esumi H, et al. Induction of intestinal adenocarcinomas by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Nagase analbuminemic rats. Jpn. J. Cancer Res. 1991;82:363–366
  12. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988;319:525–532
  13. Moonen HJJ, Briedé JJ, van Maanen JMS, Kleinjans JCS, de Kok TMCM. Generation of free radicals and induction of DNA adducts by activation of heterocyclic aromatic amines via different metabolic pathways in vitro. Mol. Carcinog. 2002;35:196–203
  14. Kadlubar FF, Kaderlik KR, Mulder GJ, Lin D, Butler MA, Teitel CE, et al. Metabolic activation and DNA adduct detection of PhIP in dogs, rats, and humans in relation to urinary bladder and colon carcinogenesis. In:  Adamson RH,  Gustafsson J-Å,  Nobuyuki I,  Nagao M,  Sugimura T,  Wakabayashi K,  Yamazoe Y, et al. editor. Heterocyclic amines in cooked foods: possible human carcinogens. 1995:New York, NY: Princeton Scientific Publishing; 1995;p. 207–213
  15. MacLeod SL, Tang Y-M, Yokoi T, Kamataki T, Doublin S, Lawson B, et al. The role of a recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proc. Am. Assoc. Cancer Res. 1998;39:396
  16. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 1999;125:803–808
  17. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 1999;47:445–449
  18. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. In:  Vineis P,  Malats N,  Lang M, et al. editor. Metabolic Polymorphisms and Susceptibility to Cancer. Lyon: IARC Scientific Publications 148; 1999;p. 173–195
  19. MacLeod S, Sinha R, Kadlubar FF, Lang NP. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat. Res. 1997;376:135–142
  20. De Kok TMCM, Van Faassen A, Glinghammar B, Pachen DMFA, Eng M, Rafter JJ, et al. Bile acid concentrations, cytotoxicity, and pH of fecal water from patients with colorectal adenomas. Dig. Dis. Sci. 1999;44:2218–2225
  21. Doll MA, Fretland AJ, Deitz AC, Hein DW. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal. Biochem. 1995;231:413–420
  22. Vatsis KP, Weber WW, Bell DA, Dupret J, Price Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995;5:1–17
  23. Christiansen L, Bygum A, Jensen A. Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum. Genet. 2000;107:612–614
  24. Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reverse-phase high-performance liquid chromatography. J. Chrom. B. 1998;709:27–34
  25. Sachse C, Smith G, Wilkie MJV, Barrett JH, Waxman R, Sullivan F, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis. 2002;23:1839–1849
  26. Ishibe N, Sinha R, Hein DW, Kulldorff M, Strickland P, Fretland AJ, et al. Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics. 2002;12:145–150
  27. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, et al. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol. Biomark. Prev. 2001;10:1259–1266
  28. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis. 1998;19:37–41
  29. Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B, Leppert M. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiol. Biomark. Prev. 1998;7:1079–1084
  30. Chen J, Stampfer MJ, Hough HL, Garcia-Closas M, Willett WC, Hennekens CH, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res. 1998;58:3307–3311
  31. Lang NP, Butler MA, Massengill J, Lawson M, Craig Stotts R, Hauer-Jensen M, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomark. Prev. 1994;3:675–682
  32. Kadlubar FF, Butler MA, Kaderlik KR, Chou H-C, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect. 1992;98:69–74
  33. Le Marchand L, Hankin JH, Pierce LM, Sinha R, Nerurkar PV, Franke AA, et al. Well-done red meat, metabolic phenotypes and colorectal cancer in Hawaii. Mutat. Res. 2002;506–507:205–214
  34. Moonen HJJ, Moonen EJC, Maas L, Dallinga JW, Kleinjans JCS, De Kok TMCM. CYP1A2 and NAT2 genotype/phenotype relations and urinary excretion of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in a human dietary intervention study. Fd. Chem. Toxicol. 2004;42:869–878
  35. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol. 1984;17:459–464
  36. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomark. Prev. 2000;9:29–42
  37. Probst-Hensch NM, Haile RW, Ingles SA, Longnecker MP, Han CY, Lin BK, et al. Acetylation polymorphisms and prevalence of colorectal adenomas. Cancer Res. 1995;55:2017–2020
  38. Potter JD, Bigler J, Fosdick L, Bostick RM, Kampman E, Chen C, et al Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiol. Biomark. Prev. 1999;8:69–75
  39. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol. 2003;55:68–76
  40. Vistisen K, Loft S, Poulsen HE. Cytochrome P450 1A2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. Adv. Exp. Med. Biol. 1991;283:407–411

PII: S0304-3835(04)00975-9

doi: 10.1016/j.canlet.2004.12.010

Cancer Letters
Volume 229, Issue 1 , Pages 25-31 , 8 November 2005

Article Tools

* Image Usage & Resolution